TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03650712

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral glucose tolerance test
Description: oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Continuous glucose monitoring
Description: a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Continuous glucose monitoring
Description: a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dexa scan
Description: low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dexa scan
Description: low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis
Study: NCT02761993

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ST266
Description: 1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
Study: NCT02301858

Intervention type: GENETIC
Group type: OTHER
Intervention: Genome analysis of tissue samples.
Description: Genome analysis of tissue samples.
Study: NCT02664987

Intervention type: OTHER
Intervention: Patients receiving cancer pain treatment
Study: NCT02761993

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ST266
Description: 1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0.9% NaCl)
Description: Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
Study: NCT00843310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (Revlimid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01905397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional wound therapy
Description: Sterile bandages and wound coverings
Study: NCT03941834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant
Description: BHV3000 (rimegepant) 75mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04433494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg
Description: TY-302 is taken orally. Tamoxifen is taken orally.
Study: NCT01029509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB 31121
Description: Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
Study: NCT04239092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered at a dose of 100 mg/m2/dose by mouth on Days 1 through 5 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan 1.2 mg/m2/dose administered intravenously over 30 min once on Days 1 through 5 of a 21 day cycle.
Study: NCT03785938

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Liquid probiotic supplied by the company Symprove

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo made of maltdextrin. Will be similar in taste and consistency
Study: NCT02601027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane (TAP) block

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus Abdominis Plane (TAP) block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nimbus Infusion Pump IV Administration

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nimbus Infusion Pump IV Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetominophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetominophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Study: NCT01587560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PyroTITAN, Ascension Orthopedics, Inc.
Description: All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PyroTITAN, Ascension Orthopedics, Inc.
Description: All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TITAN, Ascension Orthopedics, Inc.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TITAN, Ascension Orthopedics, Inc.
Study: NCT03856918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP 3 cm of water
Description: PEEP of 3 cm of water will be applied during one-lung ventilation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP 6 cm of water
Description: PEEP of 6 cm of water will be applied during one-lung ventilation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP 9 cm of water
Description: PEEP of 9 cm of water will be applied during one-lung ventilation.
Study: NCT03282916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Valacyclovir hydrochloride 500mg caplet
Study: NCT01117441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: see detailed protocol description
Study: NCT02601027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Study: NCT03438006

Intervention type: OTHER
Intervention: Safety data collection (following routine vaccination)
Description: This study assessed the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine when administered routinely according to the Prescribing Information in female Chinese subjects aged between 9 and 45 years.~The intervention consisted in the active surveillance of adverse events following immunization and pregnancy outcomes if the vaccine was administered inadvertently during pregnancy. Information of potential adverse events and pregnancy outcomes were collected at immunisation visits, telephone contacts and through spontaneous reporting by the patient/LAR/physician.
Study: NCT02601027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Study: NCT03254290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoMTA
Description: A new formulation of MTA was developed in which bismuth oxide was omitted.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formocresol
Description: Control group
Study: NCT02435316

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case vignette-based teaching of cell recognition
Description: Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.
Study: NCT03254290

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Control group
Study: NCT01365247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
Description: A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention Treatment
Description: Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Monitoring Control Group
Description: Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
Study: NCT03242889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DARA SC
Description: Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
Study: NCT03656107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Lumosity© is a commercially available software, developed by a group of neuropsychologists, which has been used across several studies of brain training and disciplines. The brain training software targets multiple brain areas, is based online, and is relatively easy to use and administer. It has been designed to adapt to the individual's memory performance to personalise the training program to their needs. Brain exercises will be selected with the support of Lumosity© to target the following brain areas; attention, memory, visuospatial, verbal fluency, and language.
Study: NCT02435316

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case vignette-based teaching of cell recognition
Description: Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compare-contrast basic science teaching of cell recognition
Description: The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compare-contrast basic science teaching of cell recognition
Description: The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.
Study: NCT04915027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a usual follow-up with Rehabkompassen®
Description: Rehabkompassen® is a patient-centered digital graphic tool for capturing the patient's rehabilitation needs in the follow-up after stroke.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®
Description: Post-Stroke Checklist consists of eleven questions concerning common and treatable post-stroke problems affecting quality of life.
Study: NCT03420625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot IPC
Description: Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid calf IPC
Description: Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
Study: NCT01117441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: see detailed protocol description
Study: NCT03420625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Slow calf IPC
Description: Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
Study: NCT03282916

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pill 500mg caplet
Study: NCT03183947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: collection of functional brain data for 1 hour per day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: collection of functional brain data for 1 hour per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 \& 4; controls: Days 2 \& 3)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 \& 4; controls: Days 2 \& 3)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PANAS
Description: to assess the mood before and after the fMRI and after 4 weeks during a telephone interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PANAS
Description: to assess the mood before and after the fMRI and after 4 weeks during a telephone interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BDI-II
Description: to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BDI-II
Description: to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERQ
Description: To assess emotion regulation strategies before and after neurofeedback training (patients: day 3\&4; controls: day 2\&3) and after 4 weeks during a telephone interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERQ
Description: To assess emotion regulation strategies before and after neurofeedback training (patients: day 3\&4; controls: day 2\&3) and after 4 weeks during a telephone interview
Study: NCT03420625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calf NMES
Description: Neuromuscular electrical stimulation in the calf using the DJOTM, CefarCompex Mi-Theta 500 stimulator
Study: NCT00763529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone
Description: Mometasone furoate cream 0.1% applied once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone propionate cream 0.05% applied twice daily
Study: NCT06352983

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed dental prosthesis
Description: Fixed dentals prosthesis made out of high translucent zirconium dioxide with or without a porcelain veneer.
Study: NCT01117441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thioguanine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thioguanine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: see detailed protocol description
Study: NCT06352983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixed dental prosthesis
Description: Fixed dentals prosthesis made out of high translucent zirconium dioxide with or without a porcelain veneer.
Study: NCT01117441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thioguanine
Description: see detailed protocol description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: see detailed protocol description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: see detailed protocol description
Study: NCT01598545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
Study: NCT03683329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic de-escalation
Description: All the therapeutic protocols made the object of a consensus between the different partners of the study.~Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.
Study: NCT04130217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: addition of positive end expiratory pressure in ventilated patients
Description: patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: addition of positive end expiratory pressure and recruitment maneuver in ventilated patients
Description: patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
Study: NCT01086345

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiosurgery
Description: Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
Study: NCT00967629

Intervention type: DRUG
Group type: OTHER
Intervention: Sevelamer Carbonate
Description: This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.

Intervention type: DRUG
Group type: OTHER
Intervention: Calcium Carbonate
Description: This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
Study: NCT01086345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT00350987

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a strategy based on PCT guided AB therapy
Description: In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a strategy based on PCT guided AB therapy
Description: In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.